FindTrial
Sign In

Epidemiology and Long-term Outcome of Patients With VHD

Epidemiology and Long-term Prognosis of Patients With Valvular Heart Diseases (BIA-WAD Study)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04527367
Acronym
BIA-WAD
Enrollment
2500
Registered
2020-08-26
Start date
2006-01-31
Completion date
2022-01-31
Last updated
2022-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic Valve Stenosis, Chronic Kidney Diseases, Coronary Artery Disease, Mitral Insufficiency and Aortic Stenosis, Mitral Stenosis, Valvular Disease, Valvular Heart Disease

Keywords

Valvular Heart Disease, Aortic Valve Stenosis, Mitral Insufficiency, Coronary Artery Disease, Chronic Kidney Diseases

Brief summary

Valvular heart diseases are significant problem in Polish population. Coexistence of coronary artery disease in patients with VHD increases the risk of death and affects further therapeutic strategy. The aim of the study is analysis the epidemiology and the long-term prognosis among patients with VHD.

Detailed description

Valvular heart diseases are significant problem in Polish population. Coexistence of coronary artery disease in patients with VHD increases the risk of death and affects further therapeutic strategy. Patients with moderate and severe valvular heart diseases are included into the study. The set of variables subject to interpretation consisted of demographic data, medical history, result of coronary angiography, and type of applied percutaneous and surgical treatment

Interventions

PROCEDUREInnovative medical technologies in invasive cardiology and cardiac surgery

A follow-up study included the analysis of medical documentation of the Cardiosurgery and the Invasive Cardiology Departments to provided information on the duration and type of procedure performed.

Sponsors

Medical University of Bialystok
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Valvular heart disease in moderate and severe stages

Exclusion criteria

* Age \< 18 years old

Design outcomes

Primary

MeasureTime frameDescription
Death3665 daysAll-cause of mortality

Secondary

MeasureTime frameDescription
MACCE3665 daysMocardial infarction, stent thrombosis, stroke or transient ischemic attack, urgent revascularization

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026